Valuation: Arcellx, Inc.

Market Cap 6.75B 5.9B 5.44B 5.02B 9.46B 650B 9.67B 65.07B 25.6B 318B 25.36B 24.8B 1,096B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.49B 5.07B 4.67B 8.8B 605B 9B 60.56B 23.82B 296B 23.6B 23.08B 1,020B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
3 months-0.03%
6 months+66.91%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 30.88
Extreme 30.88
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Date Insider Type Main position Quantity % Market Cap.
28/04/26 Tender

Chief Executive Officer

5,603,097 9.5813%
28/04/26 Tender

Director

33,275 0.0569%
28/04/26 Tender

Chief Technology Officer

597,207 1.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+62.76%+244.93% 6.75B
-1.29%-3.11%-0.39%+4.92% 49.7B
+3.33%-0.93%+374.11%+595.75% 38.09B
-1.54%+4.56%+7.57%+57.82% 35.29B
-1.98%-0.72%+26.41%-6.78% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+1.89%-2.31% - - 16.14B
+0.44%+0.09%+68.80%+117.80% 15.36B
+1.12%+1.91%+15.90%+19.65% 13.89B
+0.52%+1.93%+16.39%-30.23% 13.02B
Average +0.22%-0.50%+63.99%+114.59% 25.06B
Weighted average by Cap. -0.06%-0.63%+74.48%+122.96%

Financials

2024 2025
Net sales 107.94 94.33 87.04 80.23 151.22 10.39K 154.58 1.04K 409.2 5.09K 405.35 396.46 17.52K 22.29 19.48 17.97 16.57 31.22 2.15K 31.92 214.81 84.49 1.05K 83.7 81.86 3.62K
Net income -107M -93.81M -86.57M -79.79M -150M -10.34B -154M -1.03B -407M -5.06B -403M -394M -17.43B -229M -200M -185M -170M -321M -22.05B -328M -2.21B -868M -10.8B -860M -841M -37.17B
Net Debt -572M -499M -461M -425M -801M -55.04B -819M -5.51B -2.17B -26.96B -2.15B -2.1B -92.8B -468M -409M -378M -348M -656M -45.08B -670M -4.51B -1.77B -22.08B -1.76B -1.72B -76.01B
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ACLX Stock